The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…

FDA has indicated Karyopharm Therapeutics‘ nuclear export inhibitor Xpovio for relapsed or refractory multiple myeloma (RRMM). The indication covers its use in conjunction with the steroid dexamethasone. Patients receiving the drug should receive at least four previous therapies. Furthermore, the indication covers patients with myeloma that is refractory to at least two proteasome inhibitors, two immunomodulatory agents and…

The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien…